Clinical Trials Logo

Recurrent High Grade Glioma clinical trials

View clinical trials related to Recurrent High Grade Glioma.

Filter by:
  • None
  • Page 1

NCT ID: NCT03234595 Not yet recruiting - Clinical trials for Recurrent High Grade Glioma

A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma

Start date: November 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase I/IIa Study to Determine the Maximum Tolerated Dose (MTD) and to Evaluate the Safety and Efficacy Profile of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma. High grade gliomas, glioblastoma multiforme (grade IV) and anaplastic anaplastic astrocytoma (Grade III), are the most comment malignant brain tumor. The cause of gliomas remains unknown. Despite of several researches on environmental hazards and genetic alterations, no direct causes were found. Patient suffering from glioma usually develops symptoms such as headaches, seizures, memory loss and changes in behavior in its early phase. At later stages, patients may encounter loss of movement and sensation, language dysfunction and cognitive impairments depending on location and size of the tumor. The average survival of glioblastoma patients is 15 months regardless of the use of multimodal therapy. (Z)-BP/polymer wafer, designated as Cerebraca wafer, is a biodegradable wafer for interstitial implantation comprises (Z)-n-butylidenephthalide ((Z)-BP; the active moiety) and Carboxyphenoxypropane-Sebacic Acid Copolymer (CPPSA; the excipient). Cerebraca wafer, the first human-use drug product, is a biodegradable implant comprises (Z)-n-butylidenephthalide ((Z)-BP) and CPPSA. According to pre-clinical study, (Z)-BP could reduce glioma migration and invasion, it also could reduce the tumor stem cell marker gens.

NCT ID: NCT02567539 Recruiting - Clinical trials for Recurrent High Grade Glioma

Hypofractionated Stereotactic Radiotherapy for Patients With Recurrent High Grade Glioma

Start date: April 2015
Phase: N/A
Study type: Interventional

The study is aimed to evaluate efficacy and safety of re-irradiation for patients with recurrent high grade gliomas after other treatment.

NCT ID: NCT02416999 Not yet recruiting - Clinical trials for Recurrent High-grade Glioma

Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas

Start date: May 2015
Phase: N/A
Study type: Interventional

This study is to evaluate the effectiveness of ultra-low dose Bevacizumab plus Temozolomide for recurrent high-grade gliomas.

NCT ID: NCT02333513 Not yet recruiting - Clinical trials for Recurrent High-grade Glioma

A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation

Start date: February 2015
Phase: N/A
Study type: Interventional

This trial is aimed at evaluating the safety and effectiveness of PCV chemotherapy in patients with recurrent high-grade glioma with IDH1/2 mutation.

NCT ID: NCT01172964 Completed - Adult Glioblastoma Clinical Trials

A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas

Start date: August 2010
Phase: N/A
Study type: Interventional

RATIONALE: Genetically-modified neural stem cells (NSCs) that convert 5-fluorocytosine (5-FC) into the chemotherapy agent 5-FU (fluorouracil) at sites of tumor in the brain may be an effective treatment for glioma. PURPOSE: This clinical trial studies genetically-modified NSCs and 5-FC in patients undergoing surgery for recurrent high-grade gliomas.